Immunsuppression und Ergebnisse in der Nierentransplantation

Adesina S, Alkhudhayri A, Patel JK et al (2014) Steroid withdrawal in kidney allograft recipients. Expert Rev Clin Immunol 10:1229–1239

Bamoulid J, Staeck O, Halleck F et al (2015) The need for minimization strategies: current problems of immunosuppression. Transpl Int 28:891–900

Budde K, Lehner F, Sommerer C et al (2015) Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant 15:119–128

Bunnapradist S, Ambuhl PM (2008) Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 22:815–821

Bunnapradist S, Lentine KL, Burroughs TE et al (2006) Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82:102–107

Casey MJ, Meier-Kriesche HU (2011) Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens 20:610–615

Chapman JR (2010) The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation 89:644–645

Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335:2–13

Curtis J (2006) Corticosteroids and kidney transplantation. Clin J Am Soc Nephrol 1:907–908

Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562–2575

Fishman JA (2007) Infection in solid-organ transplant recipients. N Engl J Med 357:2601–2614

Hardinger KL, Brennan DC, Klein CL (2013) Selection of induction therapy in kidney transplantation. Transpl Int 26:662–672

Hirsch HH, Randhawa P (2013) BK polyomavirus in solid organ transplantation. Am J Transplant 13(Suppl 4):179–188

Issa N, Kukla A, Ibrahim HN (2013) Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 37:602–612

Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 28:126–133

Kasiske BL, Chakkera HA, Louis TA et al (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910–1917

Kotton CN, Kumar D, Caliendo AM et al (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333–360

Lachmann N, Schonemann C (2013) The differential pathogenicity of HLA antibodies: what a large cross-sectional study can tell us. Clin Transpl:377–384

Lamb KE, Lodhi S, Meier-Kriesche HU (2011) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11:450–462

Liefeldt L, Brakemeier S, Glander P et al (2012) Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 12:1192–1198

Maes B, Hadaya K, De Moor B et al (2006) Severe diarrhea in renal transplant patients: results of the DIDACT study. Am J Transplant 6:1466–1472

Maripuri S, Kasiske BL (2014) The role of mycophenolate mofetil in kidney transplantation revisited. Transplant Rev (Orlando) 28:26–31

Masson P, Henderson L, Chapman JR et al (2014) Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 11:CD010699

Murakami N, Riella LV, Funakoshi T (2014) Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 14:2317–2327

Nankivell BJ, Borrows RJ, Fung CL et al (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333

Pilmore H, Dent H, Chang S et al (2010) Reduction in cardiovascular death after kidney transplantation. Transplantation 89:851–857

Remuzzi G, Cravedi P, Costantini M et al (2007) Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 18:1973–1985

Satyananda V, Shapiro R (2014) Belatacept in kidney transplantation. Curr Opin Organ Transplant 19:573–577

Sawinski D, Goral S (2015) BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant 30:209–217

Sinclair NR (1992) Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 147:645–657

Staatz CE, Tett SE (2014) Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 88:1351–1389

Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525–533

Steiner RW, Awdishu L (2011) Steroids in kidney transplant patients. Semin Immunopathol 33:157–167

Vadivel N, Tullius SG, Chandraker A (2007) Chronic allograft nephropathy. Semin Nephrol 27:414–429

Van Gelder T, Silva HT, De Fijter JW et al (2008) Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86:1043–1051

Vasudev B, Hariharan S (2007) Cancer after renal transplantation. Curr Opin Nephrol Hypertens 16:523–528

Vincenti F, Ramos E, Brattstrom C et al (2001) Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71:1282–1287

Webster AC, Playford EG, Higgins G et al (2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77:166–176

Webster AC, Woodroffe RC, Taylor RS et al (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331:810